Skip to main content
Premium Trial:

Request an Annual Quote

Quark Completes Phase II Trial of Delayed Graft Function Drug


NEW YORK (GenomeWeb) – Quark Pharmaceuticals this week announced that it has completed a Phase II trial of its siRNA-based drug for the prevention of delayed graft function in kidney transplant patients.

Data from the study are slated for presentation later in July at the 2014 World Transplant Conference.

The drug, QPI-1002, is designed to silence p53 and is currently in clinical testing for two indications: preventing delayed graft function in patients undergoing deceased donor kidney transplantation and preventing ischemia-reperfusion-induced kidney injury in patients removed from a cardiopulmonary bypass pump.

In the just-completed Phase II trial, 332 patients were randomized to receive either a 10 mg/kg single bolus IV dose of QPI-1002 or placebo at 30 minutes following reperfusion. The primary endpoint was the incidence of delayed graft function, with secondary endpoints including dialysis occurrence, duration, and severity per patient immediately after transplantation and during the follow up period, and certain kidney function parameters.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.